In vitro and in vivo efficacy of a novel fluoro-ketolide HMR 3562 against enterococci | Zendy

Matthieu J. Guitton | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In vitro and in vivo efficacy of a novel fluoro-ketolide HMR 3562 against enterococci

Author(s) -

Matthieu J. Guitton

Publication year - 2001

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/48.1.131

Subject(s) - ketolide , microbiology and biotechnology , in vivo , erythromycin , biology , in vitro , antibacterial agent , pharmacology , antibiotics , biochemistry

The in vitro activity of HMR 3562, a new 2-fluoro-ketolide drug, was investigated against 95 enterococci, including 36 vancomycin-resistant strains. HMR 3562 inhibited 90% of enterococci susceptible or resistant to erythromycin A at 0.005 and 0.6 mg/L, respectively. HMR 3562 was highly active in murine peritonitis induced by five enterococci, irrespective of resistance phenotype, displaying effective doses in the range 3.4-21.8 mg/kg. The results demonstrate the potential of HMR 3562 in the treatment of infections caused by multiresistant enterococci.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research